Biocon Biologics Launches Biosimilar for Autoimmune Diseases in US

Feb 24, 2025 18:50

Biocon Biologics launches YESINTEK (ustekinumab-kfce), a biosimilar for Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, in the US market.

Biocon Biologics Launches Biosimilar for Autoimmune Diseases in US

Photograph: Kind courtesy Biocon Biologics/Facebook

New Delhi, Feb 24 (PTI) Biocon Biologics on Monday said it has launched a biosimilar product to treat certain autoimmune diseases, in the US market.

YESINTEK (ustekinumab-kfce), which is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, is now available to patients in the US, the company said in a statement.

The company's product is biosimilar to Stelara.

"The launch of YESINTEK marks a significant step in our commitment to improving the lives of patients with inflammatory conditions and expanding access to high-quality biosimilars," Biocon Biologics CEO & MD Shreehas Tambe said.

Biocon Biologics Inc Head of North America Josh Salsi said:"For healthcare providers, switching to YESINTEK offers a seamless treatment experience covering the same indications and dosing options.

Source: PTI By Rediff Money Desk, New Delhi

DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.